OncoCyte Corporation Price & Performance (OCX)

Oncocyte has secured Bio-Rad Laboratories as a major investor, now holding nearly 10% of the company’s shares. The partnership brings financial backing for clinical trials and commercialization, reinforcing Oncocyte’s push into transplant diagnostics. Recent Medicare coverage expansion and FDA dialogue signal potential catalysts for growth in the coming year.123

Despite reporting a net loss of over $60 million in 2024, Oncocyte’s revenue grew 25% to $1.88 million. Analyst consensus remains bullish, with a 12-month price target of $4.56—over 60% above current levels. The company’s innovative diagnostics pipeline and recent equity raises underpin continued optimism.45

Recent months have seen significant insider purchases at Oncocyte, with major shareholders and executives boosting their stakes. This comes as the company faces liquidity challenges and fluctuating stock performance. Such insider confidence, despite high risk signals, could indicate belief in the firm’s long-term turnaround potential.627